Binding to receptors in the cell nucleus is crucial for the action of
lipophilic hormones and ligands. PPAR-gamma (for peroxisome proliferat
or-activated receptor) is a nuclear hormone receptor that mediates adi
pocyte differentiation(1,2) and modulates insulin sensitivity(3), cell
proliferation(4) and inflammatory processes(5,6). PPAR-gamma ligands
have been implicated in the development of atherogenic foam cells(7) a
nd as potential cancer treatments(8). Transcriptional activity of PPAR
-gamma is induced by binding diverse ligands, including natural fatty
acid derivatives(9-11), antidiabetic thiazolidinediones(12), and non-s
teroidal anti-inflammatory drugs(13). Ligand binding by PPAR-gamma, as
well as by the entire nuclear-receptor superfamily, is an independent
property of the carboxy-terminal ligand-binding domain (LBD) of the r
eceptor(14,15). Here we show that ligand binding by PPAR-gamma is regu
lated by intramolecular communication between its amino-terminal A/B d
omain and its carboxy-terminal LED. Modification of the A/B domain, fo
r example by physiological phosphorylation by MAP kinase, reduces liga
nd-binding affinity, thus negatively regulating the transcriptional an
d biological functions of PPAR-gamma. The ability of the A/B domain to
regulate ligand binding has important implications for the evaluation
and mechanism of action of potentially therapeutic ligands that bind
PPAR-gamma and that are likely to extend to other members of the nucle
ar-receptor superfamily.